• 1. Rapid assembly of the doubly-branched pentasaccharide domain of the immunoadjuvant jujuboside A via convergent B(C6F5)3-catalyzed glycosylation of sterically-hindered precursors
  Rashad R. Karimov,Derek S. Tan,David Y. Gin Chem. Commun. 2017 53 5838
• 2. Simultaneous label-free screening of G-quadruplex active ligands from natural medicine via a microfluidic chip electrophoresis-based energy transfer multi-biosensor strategy
  Yi Lu,Shiyong Yu,Fengming Lin,Fankai Lin,Xiaocao Zhao,Liqing Wu,Yunfei Miao,Huanjun Li,Yulin Deng,Lina Geng Analyst 2017 142 4257
• 3. Analysis of six bioactive components in Semen Ziziphi Spinosae by UPLC-ELSD and UPLC-Q/TOF-MS
  Xiangsheng Zhao,Liwei Xie,Haifeng Wu,Weijun Kong,Meihua Yang Anal. Methods 2014 6 5856
• 4. Simultaneous determination of 41 components in Gualou Guizhi granules by UPLC coupled with triple quadrupole mass spectrometry
  Yu Lin,Wei Xu,Wen Xu,Mingqing Huang,Yuqin Zhang,Huang Li,Kedan Chu,Lidian Chen Anal. Methods 2015 7 8285
• 5. Phytochemical analyses of Ziziphus jujuba Mill. var. spinosa seed by ultrahigh performance liquid chromatography-tandem mass spectrometry and gas chromatography-mass spectrometry
  Bao Yang,Hongshun Yang,Feng Chen,Yanglin Hua,Yueming Jiang Analyst 2013 138 6881

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Triterpenoids
• Triterpenoids
• Pharmaceutical and Biochemical Products Pharmaceutical Active Ingredients Standard Substances

Jujuboside A (CAS No. 55466-04-1): A Comprehensive Overview of Its Chemical Profile and Therapeutic Potential

Jujuboside A, a naturally occurring flavonoid glycoside, is a compound of significant interest in the field of pharmaceutical chemistry and natural product research. With the chemical identifier CAS No. 55466-04-1, this molecule has garnered attention due to its diverse biological activities and potential therapeutic applications. Extracted primarily from the roots of Albizia julibrissin, commonly known as the mimosa tree, Jujuboside A belongs to the flavonolignan class, a structurally complex group of polyphenolic compounds known for their antioxidant, anti-inflammatory, and anticancer properties.

The structural elucidation of Jujuboside A has been a subject of extensive research, with its chemical formula established as C??H??O??. This compound features a beta-D-glucopyranosyl moiety linked to a quercetin derivative, forming a unique flavonolignan structure. The presence of multiple hydroxyl groups and glycosidic bonds contributes to its high solubility in water and alcohol, making it suitable for various formulation strategies in drug development.

Recent advancements in spectroscopic techniques, such as nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS), have enabled researchers to refine the structural characterization of Jujuboside A. These studies have revealed that the compound exhibits a high degree of stereochemical complexity, with specific conformations that influence its biological interactions. The absolute configuration of Jujuboside A has been determined to be (2S,3R,4R)-2-(3-hydroxypropyl)-3,4-dihydroxy-5-(4-hydroxyphenyl)-7-oxo-4H-chromen-8-one 6-O-beta-D-glucopyranoside, underscoring the precision required in its synthesis and analysis.

The pharmacological profile of Jujuboside A has been extensively studied in vitro and in vivo. One of its most notable properties is its potent antioxidant activity, attributed to its ability to scavenge reactive oxygen species (ROS) and inhibit enzymes such as lipoxygenase and cyclooxygenase. These mechanisms are particularly relevant in the context of oxidative stress-related diseases, including neurodegenerative disorders like Alzheimer's disease and Parkinson's disease. Preclinical studies have demonstrated that Jujuboside A can protect against oxidative damage in neuronal cells by upregulating antioxidant enzymes such as superoxide dismutase (SOD) and catalase.

In addition to its antioxidant effects, Jujuboside A has shown promising anti-inflammatory properties. Research indicates that this compound can modulate inflammatory pathways by inhibiting the nuclear factor kappa B (NF-κB) signaling pathway, which is central to the transcription of pro-inflammatory genes. Animal models of inflammation have revealed that oral administration of Jujuboside A reduces key inflammatory markers such as tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6). These findings suggest that Jujuboside A could be a valuable therapeutic agent for conditions like rheumatoid arthritis and inflammatory bowel disease.

The anticancer potential of Jujuboside A has also been extensively explored. Studies have shown that this compound can induce apoptosis in various cancer cell lines by activating caspase-dependent pathways and inhibiting anti-apoptotic proteins such as Bcl-xL. Furthermore, Jujuboside A has demonstrated the ability to disrupt microtubule formation, leading to cell cycle arrest in cancer cells. Preclinical trials using human colorectal cancer cell lines have reported significant reductions in cell proliferation and tumor growth following treatment with Jujuboside A. These results are particularly encouraging given the increasing interest in natural product-derived chemotherapeutic agents that offer alternative or complementary treatments to conventional chemotherapy.

The antimicrobial activity of Jujuboside A is another area of growing interest. Research has demonstrated that this compound exhibits broad-spectrum antimicrobial effects against both Gram-positive and Gram-negative bacteria, as well as fungi. The mechanism behind this activity appears to involve disruption of bacterial cell membranes and inhibition of key enzymatic processes essential for microbial survival. These findings suggest that Jujuboside A could be developed into novel antimicrobial agents or used in combination with existing antibiotics to combat multidrug-resistant bacterial strains.

The pharmacokinetic properties of Jujuboside A are critical considerations for its potential therapeutic application. Studies have shown that oral administration leads to moderate bioavailability due to rapid metabolism in the liver via phase II conjugation reactions. However, recent research has highlighted the potential for enhancing bioavailability through prodrug strategies or co-administration with absorption-enhancing agents such as piperine or β-cyclodextrin. Additionally, intravenous administration has been explored as an alternative route for achieving higher concentrations of Jujuboside A, particularly in acute therapeutic scenarios.

The synthetic chemistry of Jujuboside A remains a challenging yet fascinating area of research. Given its complex structure, researchers have employed various synthetic approaches, including glycosylation reactions on pre-formed quercetin derivatives and microbial fermentation techniques for selective glycosylation. Advances in biocatalysis have enabled more sustainable production methods, reducing reliance on harsh chemical reagents and minimizing waste generation. These innovations not only improve yield but also enhance scalability for industrial production.

Ethical considerations are paramount when evaluating the commercialization prospects of compounds like Jujuboside A. Sustainable sourcing practices must be implemented to ensure the long-term availability of raw materials from Albizia julibrissin without causing environmental degradation or depletion of natural resources. Collaborative efforts between academia, industry, and conservation organizations are essential for developing responsible cultivation strategies that balance economic benefits with ecological preservation.

The regulatory landscape for natural product-derived compounds presents unique challenges due to varying standards across different regions. However, recent initiatives by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have streamlined pathways for natural products with demonstrated therapeutic efficacy. This trend bodes well for compounds like Jujuboside A, which may eventually gain regulatory approval for specific indications following rigorous clinical trials.

In conclusion, Jujuboside A (CAS No. 55466-04-1) represents a compelling example of how natural product research can yield bioactive compounds with significant therapeutic potential across multiple disease areas. Its multifaceted biological activities—ranging from antioxidant and anti-inflammatory effects to anticancer and antimicrobial properties—make it an attractive candidate for further development into novel therapeutics or functional foods/ingredients targeting chronic diseases associated with oxidative stress or inflammation.

• 146445-92-3(β-D-Glucopyranoside, (3β,16β,23R)-16,23:16,30-diepoxy-20-hydroxy-13-methyldammar-24-en-3-yl O-6-deoxy-α-L-mannopyranosyl-(1→2)-O-[β-D-glucopyranosyl-(1→3)]-)
• 155545-03-2(Bacopaside IV)
• 94443-88-6(bacopaside X)
• 68144-21-8(Jujuboside B1)
• 157408-08-7(Bacoside A3)
• 55466-05-2(Jujuboside B)
• 68665-70-3(a-L-Arabinopyranoside, (3b,16b,23R)-16,23:16,30-diepoxy-20-hydroxydammar-24-en-3-ylO-b-D-glucopyranosyl-(1®3)-O-[b-D-xylopyranosyl-(1®2)]- (9CI))
• 156985-57-8(a-L-Arabinopyranoside, (3b,16b,23R)-16,23:16,30-diepoxy-20-hydroxydammar-24-en-3-ylO-6-deoxy-a-L-galactopyranosyl-(1®2)-O-[b-D-glucopyranosyl-(1®3)]-)
• 146503-30-2(α-L-Arabinopyranoside, (3β,16β,23R)-16,23:16,30-diepoxy-20-hydroxydammar-24-en-3-yl O-6-deoxy-β-D-glucopyranosyl-(1→2)-O-[β-D-glucopyranosyl-(1→3)]-)
• 194851-84-8(Jujuboside D)